You are here

Article Text

Article menu
Download PDFPDF
Letter
Uveitis and tumour necrosis factor blockade in ankylosing spondylitis
  1. L C Coates,
  2. D G McGonagle,
  3. A N Bennett,
  4. P Emery,
  5. H Marzo-Ortega
  1. Academic Unit of Musculoskeletal Disease, University of Leeds and Chapel Allerton Hospital, Leeds, UK
  1. Dr H Marzo-Ortega, Academic Unit of Musculoskeletal Disease, University of Leeds and Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK; medhmo{at}leeds.ac.uk

https://doi.org/10.1136/ard.2007.077370

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Anterior uveitis is the commonest extra-articular manifestation of ankylosing spondylitis (AS) and occurs in up to 40% of patients during the course of their disease.1 Uveitis associated with AS is typically anterior, unilateral and responsive to topical treatment.2 Tumour necrosis factor (TNF) blocking agents have been used in the treatment of uveitis refractory to conventional therapies but etanercept may be less effective in the treatment of uveitis in spondyloarthropathy (SpA) patients,3 possibly related to its alternative mode of action as a receptor blocker rather than antibody to TNF. Paradoxically they also seem to …

    View Full Text

    Footnotes

    • Competing interests: None declared.